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PDE4 inhibition enhances hippocampal synaptic
plasticity in vivo and rescues MK801-induced
impairment of long-term potentiation and object
recognition memory in an animal model of psychosis
V Wiescholleck
1,2 and D Manahan-Vaughan
1,2
Inhibition of phosphodiesterase type 4 (PDE4) by rolipram (4-(3-(cyclopentyloxy)-4-methoxyphenyl)-pyrrolidin-2-one) has
been the focus of many behavioral and molecular studies in the recent years. Rolipram exhibits memory-enhancing effects in
rodents.Invitrostudieshaveshownthatlong-termpotentiation(LTP),whichmaycompriseacellularsubstrateforlearning,is
also enhanced by rolipram. However, effects have not been assessed in vivo. Rolipram has antipsychotic properties.
Psychosis affects cognition and in animal models of psychosis LTP is impaired. In this study, we investigated if PDE4
inhibition improves LTP in healthy animals in vivo and if PDE4 inhibition rescues impaired LTP and prevents object
recognition memory deﬁcits in an animal model of psychosis. Recordings were made from the hippocampus of adult, freely
behaving Wistar rats. Thirty minutes after treatment with rolipram or vehicle, a tetanus was applied to the medial perforant
path to elicit short-term potentiation (STP) in the dentate gyrus. At this time-point, radioimmunoassay revealed that rolipram
signiﬁcantly elevated cyclic adenosine monophosphate levels in the dorsal hippocampus, in line with reports by others that
roliprammediatesdecreasedPDE4activity.Inhealthyanimals,bothintracerebroventricularandsubcutaneoustreatmentwith
rolipram facilitated STP into LTP, suggesting that PDE4 inhibition may have a permissive role in plasticity mechanisms that
are relevant for learning and memory. One week after a single systemic treatment with the irreversible N-methyl-D-aspartate
antagonist, MK801, LTP and object recognition memory were signiﬁcantly impaired, but could be rescued by PDE4 inhibition.
These data suggest that the relief of cognitive disturbances in psychosis models by rolipram may be mediated in part by a
rescue of hippocampal LTP.
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Introduction
Inhibition of the phosphodiesterase type 4 (PDE4) by rolipram
(4–3–Cyclopentyloxy)-4–methoxyphenyl)-pyrrolidin-2–one)
enhances cognition in animals. Several studies have demon-
strated that rolipram improves animals’ performance in
memory-dependent behavioral tests, such as the object
recognition task (ORT)
1 and freezing-to-context task.
2 It
selectively inhibits PDE4, which comprises a family of four
enzymes (PDE4A-D) that control the hydrolysis of cyclic
adenosine monophosphate (cAMP). Consequently, PDE4
inhibition reduces degradation of cAMP, and therefore leads
toelevatedcAMP levels.
2,3 cAMPisa secondmessengerthat
has a key role in several intracellular cascades, including the
cAMP/ protein kinase A (PKA)/ cAMP response element-
binding protein (CREB) pathway.
4 The cAMP/PKA/CREB
pathway has been shown to be critically involved in learning
and memory.
5
In vitro studies in CA1 region have further demonstrated
that rolipram facilitates long-term potentiation (LTP) in
hippocampal slice preparations.
2,6 LTP comprises an activity-
dependent long-lasting strengthening of synaptic transmis-
sion.
7 Hippocampal LTP has been proposed to be a cellular
mechanism underlying learning and memory.
8,9 Interestingly,
besides being involved in learning and memory, the cAMP/
PKA/CREB pathway is also crucial for LTP and transcription
of LTP-related genes.
4 Hence, cognition improvement via
PDE4 inhibitonmight bedue tothemodulation of thispathway
and subsequent enhancement in the ability to express
synaptic plasticity. However, the question as to whether
rolipram also facilitates LTP in intact brains of healthy freely
moving animals has not yet been answered.
Cognition is impaired under many pathological conditions,
one of which is psychosis. Although acute psychotic events
occurextremelyfrequently—3outof100peoplewillexperience
a psychotic episode in their lifetimes—its pathophysiology and
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www.nature.com/tplong-term consequences are not well understood. Acute
psychotic episodes can be caused under various conditions,
such as for example, schizophrenia, bipolar disorder, schizo-
phreniform disorder, schizoaffective disorder, drug-induced
psychosis, brief reactive psychosis, organic psychoses and
delusional disorder.
10 Single psychotic events must be
appropriately treated in order to prevent long-term conse-
quences. Recent psychiatric research indicates that there is a
critical period after ﬁrst-episode psychosis, where early
intervention is crucial.
11–13 If treated successfully, there is a
higher chance of preventing secondary morbidity, relapse or
persistent disability associated with, for example, schizo-
phrenia-related disorders.
14
To study the cellular and molecular mechanisms underlying
single psychotic events, an animal model of acute psychosis
was developed in which a single injection of the irreversible
uncompetitive N-methyl-d-aspartate receptor (NMDAR)-
antagonist, MK801, is applied systemically in rats.
15–17
Uncompetitive NMDAR-antagonists have been shown to
induce psychotic symptoms in healthy humans and to
exacerbate symptoms of schizophrenic patients.
18,19 After a
single injection with MK801, rats display short-lasting tran-
sient behavioral aspects of psychosis-related behavior, such
as disturbed pre-pulse inhibition of the acoustic startle
response, disturbed stereotypy and increased ataxia.
15,16
This is followed by long-term impairments in both spatial
memory and in LTP at the perforant path-dentate gyrus
synapse of the hippocampus.
16 These ﬁndings suggest that
long-term disruptions in cognitive ability in psychosis are
associated with the loss of LTP.
Recent evidence indicates that alterations in the activity of
PDE4 may contribute to the cellular mechanisms underlying
psychosis.
20–22 PDE4B has been shown to bind with a protein
called DISC1 (disrupted in schizophrenia 1).
23 Chromosomal
aberrations of DISC1 clearly correlate to schizophrenia.
24,25
DISC1 shows reduced expression in psychotic patients,
thereby probably mediating less binding of the dephosphory-
lated inactive PDE4B and a subsequent pathological eleva-
tion of the amount of phosphorylated active PDE4B.
26 Thus,
PDE4BactivityseemstobedirectlyregulatedbyDISC1
27and
therefore may have an important role in psychosis-related
diseases.
In this study, we asked the question as to whether PDE4
inhibition may enable a rescue of LTP and memory performance
in MK801-treated animals. This is not so unreasonable, given
reports that rolipram has attenuating effects on MK801-induced
impairments in psychosis-related behavior of rodents,
20,21,28,29
indicating that PDE4 might act as a possible new receptor-
independent therapeutic target in psychotic disorders by
directly affecting PDE4-speciﬁc cAMP hydrolysis.
We ﬁrst addressed the question as to whether rolipram
treatment of adult freely behaving rats results in an enhance-
ment of LTP in healthy animals, as this has not yet been
exploredinvivo.Wethen examinedifPDE4inhibition rescues
LTP that is impaired in the MK801 animal model of psychosis.
Next, to validate a peripheral route of application, we
investigated if the plasticity-enhancing effects of an intracer-
ebroventricular rolipram injection can be replicated by
systemic treatment. And ﬁnally, in order to examine functional
aspects of our electrophysiological ﬁndings, we assessed the
effect of rolipram on object recognition memory performance
in control and MK801-treated animals.
Materials and methods
The present study was carried out in accordance with the
European Communities Council Directive of 24 November
1986 (86/609/EEC) for care of laboratory animals and after
approval of the local ethic committee (senate of Berlin or
Bezirksamt Arnsberg). All efforts were made to reduce the
number of animals used.
Animals. Six to seven-week-old male Wistar rats (Charles
River, Sulzfeld, Germany) were housed on a 12-h light/ dark
cycle (lights on at 07:00 AM) for at least 1 week after their
arrival in the animal facilities before treatment and surgery.
Surgical implantations. Animals (7–8 weeks old) were
anesthetized (52mgkg
–1 pentobarbital via intraperitoneal
(i.p.) injection) and underwent chronic implantation of a
monopolar recording electrode in the granule cell layer of
dentate gyrus (hole diameter: ca. 1mm; hole coordinates:
3.1mm posterior to bregma, 1.9mm lateral to the midline;
electrode depth: ca. 4.2mm from bone) and a bipolar
stimulating electrode in the perforant pathway (hole
diameter: 1mm diameter; hole coordinates: 6.9mm
posterior to bregma, 4.1mm lateral to the midline;
electrode depth: ca. 4.0mm from bone), as described
previously.
30 The perforant pathway-dentate gyrus synapse
was selected in line with previous studies of LTP in this
animal model of psychosis conducted by our group.
16,17 In
addition, in terms of certain schizophrenia-relevant
GABAergic markers, the dentate gyrus has been shown to
react ﬁrst to systemically applied MK801 as compared with
all other hippocampal subﬁelds and brain regions.
31 Both
electrodes were made of polyurethane-coated stainless steel
wire. A cannula was implanted in the lateral cerebral ventricle
(0.5mm posterior to bregma, 1.6mm lateral to the midline,
5.6mm length, 0.8mm diameter, 4mm depth) to enable
injections. The animals were allowed to recover from surgery
for 7–10 days before experiments were conducted. Animals
which then showed evoked potentials that are not
characteristic of the medial perforant path-dentate gyrus
synapse were excluded from the study.
Electrophysiological recordings. Throughout all experi-
ments, the animals could move freely within the recording
chamber (40 40 40cm) and had free access to food and
water. For acclimatization the animals were transferred to the
experiment room 1 day in advance. The implanted electrodes
were connected through a head stage by a ﬂexible cable and
a swivel connector to the stimulation unit and ampliﬁer.
Recordings were stored on a personal computer.
Responses were evoked by stimulating at low frequency
(0.025Hz, 0.2ms stimulus duration, 10000Hz sample rate).
For each time-point, ﬁve evoked responses were averaged.
Dentate gyrus population spike (PS) amplitude, as well as
ﬁeld excitatory postsynaptic potential (fEPSP) slope were
monitored: PS amplitude reﬂects summated action potentials
from the somatic layer of granule cells in the dentate gyrus,
PDE4 regulates LTP and memory
V Wiescholleck and D Manahan-Vaughan
2
Translational Psychiatrywhereas alterations of fEPSP indicate dendritic changes.
Each experiment started with an input-output curve (100–
900mA in steps of 100mA) to determine the stimulus intensity
required to elicit a PS that was 40% of the maximum
obtained. To ensure stability of recordings and to assess
basal synaptic transmission, all animals were tested in a
baseline experiment ﬁrst, where only test-pulse stimulation
was applied. LTP was induced by high-frequency stimulation
(HFS) (10 bursts of 15 pulses at 200Hz with a 10s inter-burst
interval). Short-term potentiation (STP) was induced by a
weak HFS (wHFS, 3 bursts of 15 pulses at 200Hz and a 10s
inter-burst interval).
Atthebeginningofeachexperiment,baselinePSamplitude
and fEPSP slope were obtained by averaging the response to
stimulation (ﬁve sweeps at 40s intervals), every 5min over a
period of 30min. Drug or vehicle injections were then applied
either via an intracerebroventricular cannula at the site
ipsilateral to electrophysiological recordings, or subcuta-
neously (s.c.). Injections were followed by additional six
recordings in a 30-min or 60-min period. At this point, HFS or
wHFS was given (no HFS/wHFS stimulation in baseline
experiments), and three additional measurements at 5-min
intervals were taken, followed by recordings at 15-min
intervals for 24h.
Histology. At the end of the electrophysiological study,
brains were removed and histological veriﬁcation of
electrodes and cannula localization was carried out. Brain
sections (16mm) were stained according to the Nissl method
using 1% toluidine blue and then examined using a light
microscope. Data from animals in which an incorrect
electrode or cannula localization was found, or where
hippocampal misformations were evident were excluded
from the study.
cAMP radioimmunoassay. Right dorsal hippocampi were
dissected 30min after an intracerebroventricular (i.c.v.)
injection of 5ml of either vehicle or rolipram (2.75mg), and
were then shock-frozen in liquid nitrogen before being stored
at  801C. The tissue was subsequently homogenized in 1ml
ice-cold 70% ethanol and centrifuged for 15min at 41C and
15300 r.p.m. The supernatants were used for the cAMP
radioimmunoassay and the pellets were kept for
quantiﬁcation of protein amount via the bicinchoninic acid
(BCA) method, performed according to kit instructions
(BCA protein assay kit, Pierce, Thermo Scientiﬁc, Rockford,
IL, USA). The cAMP-radioimmunoassay (IBL international
GMBH, Hamburg, Germany), based on the principle of
radioimmunoassays for cyclic nucleotides described by
Steiner et al.
32 and modiﬁed by Harper and Brooker,
33 was
performed according to kit instructions. In brief, the
supernatant of each sample was dried via vaporization and
subsequently diluted in 100ml radioimmunoassay buffer
(100mM sodium acetate, pH 6.0) and acetylated with
triethylamine and acetate hydride (2:1). Samples were
incubated for 3h with
125I-labeled cAMP and the pre-
precipitated antiserum. As radioactive and non-radioactive
antigens compete for a ﬁxed number of antibody-binding
sites, the amount of
125I-labeled antigen bound to
the antibody is inversely proportional to the analyzed
concentration of the sample. The reaction was stopped by
the addition of a co-precipitating solution and a centrifugation
step. The precipitate was counted in a gamma counter
(Cobra II Auto-Gamma Counter, Packard GMI, USA). cAMP
levels were normalized to the amount of protein in the pellet.
Object recognition task. The ORT was performed as
described elsewhere.
34 The apparatus consisted of a grey
square polyvinyl chloride arena (80 80 80cm). The test
was performed with a constant light intensity of 18 lux. Two
different kinds of objects were used: a black polyvinyl
rectangle tower (9 11 23cm) and a transparent glass
cylinder (10cm diameter, 30cm height). The objects could
not be displaced by the animals, as they were weighted with
sand or stones.
Three habituation sessions preceded the test, in which the
animals were allowed to explore the empty arena for 5min
each. The testing was carried out directly after the last
habituation session. The testing comprised two trials of 3-min
duration each. A rat was always placed into arena facing the
middleofthe frontwall. Duringtheﬁrst trial (T1)ananimalwas
allowed to explore two identical objects, which were placed
symmetrically 20cm away from the walls, After T1 the rat was
putbackintoitshomecage.After4hthesecondtrial (T2)took
place, in which the rat was placed back into the arena and
exposed to a familiar and a novel object (Figure 5a). The
testing session was videotaped. The times spent exploring
each object during T1 and T2 were scored manually.
Exploration was deﬁned as directing the nose to the object
at a distance of no more than 2cm and/or touching the object
with the nose. Sitting on the object was not considered as
exploratory behavior. In order to avoid the presence of
olfactory cues the objects and the arena were always
thoroughly cleaned with 70% ethanol, washed with water
and dried before each trial. Furthermore, as the objects were
available in triplicate, neither of the two identical objects from
T1 had to be reused in T2. All combinations and locations of
objects were used in a balanced manner to reduce potential
biases, suchaspreferencesforparticular locationsorobjects.
In addition, total exploration times have been compared
between groups in T1 and T2 in order to exclude potential
exploration bias. The testing order was determined randomly.
Rats that did not explore any of the objects in any trial were
removed from analysis.
Compounds and drug treatment. The PDE4 inhibitor
rolipram (4–3–Cyclopentyloxy)-4–methoxyphenyl)-pyrrolidin-
2–one) (Biozol, Eching, Germany) was dissolved in 1.5%
dimethylsulfoxide (DMSO) or in 3% DMSO and 0.9%
physiological saline for i.c.v injection or for systemic
injection, respectively. Dilutions of 1.5 or 3% DMSO had no
effect on control recordings. For i.c.v injections, rolipram
(2.75mg or 5.5mg) or vehicle was injected in a 5ml volume
over a 5-min period via a Hamilton syringe 30min before
stimulation to enable diffusion from the lateral cerebral
ventricle to the hippocampus to occur. For systemic
application, comparable concentrations were calculated,
based on known pharmacokinetics of rolipram in the rat
(Krause and Ku ¨hne, 1988). Rolipram (0.6mgkg
–1 or
1.2mgkg
–1) or vehicle (2mlkg
–1) were injected s.c. 30 or
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dose (1.2mgkg
–1) caused transient dizziness and catalepsy
in the animals, which disappeared approximately 20min after
treatment. In behavioral experiments, rolipram (1.2mgkg
–1)
was injected s.c. 24h before T2 (Figure 5a), as with this
concentration LTP was signiﬁcantly enhanced for at least
24h. Furthermore, acute stress effects arising from the
injection could thus be excluded.
The NMDAR antagonist [þ]-5–methyl-10,11–dihydro-
5Hdibenzo-[a,d]-cyclohepten-5,10–imine hydrogen maleate
(MK801, Tocris, Bristol, UK) was dissolved in 0.9% physio-
logical saline. MK801 (5mgkg
–1) or vehicle (10mlkg
–1)
were injected i.p. 7 days before commencement of
experiments. The concentration of MK801 was chosen in
accordance with previousstudies conducted byour group.
15–17
Directly after injection, acute transient psychosis-like behaviors
(locomotion, ataxia and stereotypy) were scored as
described elsewhere
15 in order to evaluate the effective-
ness of the treatment. Animals that did not display this
psychosis-like behavioral proﬁle were excluded from further
experiments.
Data analysis. In all electrophysiological experiments, data
were expressed as mean % pre-injection values ± standard
error of the mean (s.e.m.). Analysis of variance (ANOVA) was
used to evaluate differences between groups in the both control
animals studies (i.c.v. and s.c. control studies). The Bonferroni
post-hoc test was applied, if more than two groups were
compared. ANOVA with repeated measures was used
to evaluate differences between pretreatment control
experiments and experiments in which test compound or
vehicle was applied intracerebrally in the MK801 study.
Therefore, all values after stimulation (weak HFS or HFS) or
corresponding values in baseline experiments were
compared. In the cAMP assay, quantitative cAMP values
for the vehicle and the rolipram groups have been analyzed
via a one-way ANOVA. In the behavioral study percentage of
total exploration time for each object during T1 and T2 were
calculated. One-way ANOVA was used in order to compare
percentage of time spent in exploring the novel as compared
with the familiar object during T2 for each of the four groups.
Differences in total exploration times in T1 and T2 have been
analyzed via a one-way ANOVA. Statistical analysis was
performed using the SPSS software (version 11.5). The level
of signiﬁcance was set at Po0.05.
Results
PDE4 inhibition facilitates STP into LTP in vivo, but does
not affect basal synaptic transmission. To date, effects of
PDE4 inhibitors on hippocampal synaptic plasticity have only
been studied in vitro.
2,6,35 We investigated whether an i.c.v.
injection with the PDE4 inhibitor, rolipram, leads to
alterations in excitability or in ability to express synaptic
potentiation in the dentate gyrus of adult freely behaving
rats. Basal synaptic transmission was unaffected by
rolipram, as no signiﬁcant changes were found between
vehicle-treated control animals (n¼6) and animals treated
with rolipram (5.5mg, n¼6) in a baseline experiment
(PS: F (1,228)¼0.780, not signiﬁcant (NS), Figure 1a;
fEPSP: F (1,229)¼1.311, NS, Figure 1b).
In control animals (n¼6), weak HFS (wHFS: 3 bursts of 15
pulses at 200Hz, 10s interburst interval) elicited STP
that persisted for approximately 2h. Intracerebral treat-
ment with rolipram signiﬁcantly facilitated STP into LTP
(PS: F (2,300)¼14.322, Po0.0001, Figure 1c; fEPSP: F
(2,304)¼19.230, Po0.0001, Figure 1d). The subsequent
Bonferroni post-hoc test revealed a signiﬁcant increase in
potentiation of the PS amplitude after application of both,
2.75mg( Po0.01, n¼4) and 5.5mg( Po0.0001, n¼6) of
rolipram, as compared with the control group. The same post-
hoc analysis of the fEPSP revealed a signiﬁcantly enhanced
potentiation if the higher (Po0.0001), but not the lower dose
of rolipram was used. If only the values recorded in the last
hour of the experiment (24–25h after stimulation) were
included in the analysis, there was still a signiﬁcant effect
of treatment (PS: F (2,59)¼6.657, Po0.01; fEPSP: F
(2,60)¼14.327, Po0.0001). In this case, the post-hoc test
showed a signiﬁcantly increased PS amplitude (Po0.01) and
fEPSP (Po0.0001) for the higher dose (5.5mg) only, whereas
neither PS amplitude nor fEPSP were different from control
after lower dose (2.75mg) treatment. Thus, although both
doses were effective, the synaptic potentiation enabled by the
higher dose lasted longer. In conclusion, PDE4 inhibition
facilitates STP into persistent LTP in vivo, but does not affect
basal synaptic transmission.
Intracerebroventricular (i.c.v.) injection of the PDE4
inhibitor rolipram elevates cAMP levels in the
hippocampus 30min after application. In our plasticity
experiments, the afferent ﬁbers to the hippocampus were
stimulated 30min after application of rolipram. Rolipram has
been shown to elevate cAMP levels when given to the
hippocampal slice preparation. This occurs as a direct
consequence of rolipram-mediated decreased PDE4
activity.
36 To check that this is also the case in vivo and
within the time-frame of our plasticity experiment, we
assessed if cAMP levels were altered after treatment with
rolipram. We observed that the cAMP concentration in the
dorsal hippocampus, 30min after i.c.v. treatment with
rolipram (2.75mg) (n¼5), was signiﬁcantly higher (F
(1,8)¼11646, Po0.01; Figure 1f) as compared with
vehicle-treated animals (n¼5). Thus, at the time-point of
stimulation rolipram had diffused adequately to the
hippocampus and had efﬁciently decreased PDE4 activity.
PDE4 inhibition rescues impaired LTP 1 week after an
acute MK801 injection. In controls, we ﬁrst showed that
systemic (i.p.) treatment with vehicle does not have any
effect on the expression of LTP. HFS (10 bursts of 15 pulses
at 200Hz, 10s interburst interval) was used to elicit LTP that
lasted for over 24h. Here, no differences were found
between pretreatment control LTP and LTP induced 1
week after i.p. treatment with vehicle (n¼7) (PS: F
(1,159)¼1.115, NS, Figure 2a; fEPSP: F (1,159)¼0.006,
NS, not shown). In both experiments, application of HFS
resulted in a signiﬁcant potentiation of synaptic strength that
lasted for at least 24h.
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synaptic plasticity, that have been reported in previous
studies,
16,17 a second group of animals was injected with
MK801, i.p, and one week later their ability to express
hippocampal LTP was assessed. In line with previous ﬁndings,
systemic treatment with MK801 (n¼7) resulted in a signiﬁcant
impairment of LTP in the dentate gyrus compared with control
LTP(PS:F(1,157)¼170.266,Po0.0001,Figure2b;fEPSP:F
(1,159) ¼ 72.089, Po0.0001, not shown). Here, a lower
induction magnitude and reduced duration of LTP (2.5h) were
evident compared to pretreatment control LTP.
Athirdgroupofanimals(n¼6)wastreatedwithMK801and
1 week later the PDE4 inhibitor rolipram (5.5mg) was applied
intracerebrally 30min before an attempt to induce LTP. Under
controlconditions,vehicleinjectionwasappliedi.c.vandhere,
HFS elicited LTP that lasted for over 24h (Figure 2c). PDE4
inhibition prevented the MK801-induced long-term deﬁcits
in the ability to express LTP (PS: F (1,131)¼3.474, NS,
Figure 2c; fEPSP: F (1,132)¼0.008, NS, not shown). Here,
PDE4 inhibition attenuated the impairment in the induction
phaseandrescuedfullythemaintenancephaseofLTP. Thus,
the MK801-induced impairment in the ability to express LTP
was rescued by PDE4 inhibition.
The PDE4 inhibitor, rolipram, enhances synaptic
plasticity in vivo, even if applied via a systemic
route. On the basis of these results, PDE4 could be
considered as a therapeutic target to address, for example,
cellular mechanisms of cognition in psychosis-related
diseases. However, in this case, peripheral administration
would be essential. In order to investigate if rolipram can also
enhance plasticity if it is applied systemically, we injected
either 0.6mgkg
–1 or a 1.2mgkg
–1 amount of rolipram s.c.
30min before wHFS stimulation. In control animals (n¼8),
wHFS elicited STP in the presence of a systemic application
of vehicle (Figure 3a). Subcutaneous treatment with rolipram
signiﬁcantly facilitated STP into LTP (PS: F (2,391)¼10.999,
Po0.0001, Figure 3a; fEPSP: F (2,391)¼20.454,
Figure1 PDE4inhibitionfacilitatesSTPintoLTP,butdoesnotaffectbasalsynaptictransmissioninthedentategyrusinvivo.Basalsynaptictransmissionisunaffectedby
PDE4inhibitionelicitedi.c.v.NodifferencesinPSamplitude(a)orinfEPSP(b)occurbetweenvehicle-(whitesquares)androlipram-treated(blacksquares)ratsinresponseto
test-pulsestimulation. Linebreakson thex-axis indicatechangeintime-scale.(c)WeakHFS(wHFS) resultsinSTP ofthePSandfEPSP(d)in vehicle-treatedanimals(white
squares), which lasts for approximately 2h. i.c.v treatment with rolipram (2.75mg, grey squares), 30min before wHFS, extends synaptic potentiation to at least 4h. LTP that
lasts over 24h is enabled, if the higher dose of rolipram (5.5mg, black squares) is applied i.c.v. Line breaks on the x-axis indicate change in time-scale. (e) Original analog
traces show ﬁeld potentials evoked from the dentate gyrus during (i) wHFS with vehicle injection, (ii) wHFS in the presence of the lower dose of rolipram, (iii) wHFS in the
presenceofthehigherdoseofrolipram,(iv)test-pulsestimulationwithvehicleinjectionand(v)test-pulsestimulationwiththehigherdoseofrolipram.Analogswereobtainedat
similartimepoints(10minpre-wHFS,10minand24hpost-wHFS).Verticalscale-barcorrespondsto5mV,horizontalscale-barto10ms.(f)i.c.v.applicationofrolipramleads
to a signiﬁcantly increased cAMP concentration in the hippocampus 30min after treatment, as demonstrated by radioimmunoassay. Values represent means ±s.e.m.;
*Po0.05. fEPSP, ﬁeld excitatory postsynaptic potential; HFS, high-frequency stimulation; i.c.v., intracerebroventricular; LTP, long-term potentiation; PDE4,
phosphodiesterase type 4; PS, population spike; STP, short-term potentiation.
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test revealed that both the lower (PS: Po0.05; fEPSP:
Po0.0001, n¼4) and the higher doses (PS: Po0.0001;
fEPSP: Po0.0001, n¼8) of rolipram potentiated control
STP. Thus, if applied systemically, both doses were sufﬁcient
to enhance synaptic plasticity. Analysis of the values
recorded in the last hour of the experiment (24–25h after
stimulation) revealed that the higher dose is more effective
(PS: F (2,72)¼5.026, Po0.01; fEPSP: F (2,60)¼4.492,
Po0.05).
Systemic application of the PDE4 inhibitor rolipram
at the higher dose (1.2mgkg
–1) induces transient
chemical potentiation, which lasts for 1h after
injection. Subcutaneous rolipram injection at the dose of
1.2mgkg
–1 signiﬁcantly potentiated the PS amplitude
and the fEPSP immediately after injection (Figure 3a) (PS:
F (2,117)¼12.594, Po0.0001, Figure 3a; fEPSP:
F(2,117)¼14.185, Po0.0001, not shown). In order to
study this phenomenon of chemical potentiation in more
detail, a baseline experiment was performed in which either
vehicle (n¼9) or rolipram was applied s.c. at the dose of
1.2mgkg
–1 (n¼11). This baseline experiment revealed that
PS amplitude and fEPSP remained signiﬁcantly enhanced
for 1h (PS: F (1,131)¼66.084, Po0.0001, Figure 3b;
fEPSP: F (1,131)¼38.137, Po0.0001, not shown).
Thereupon, PS amplitude and fEPSP values returned to
baseline levels and remained stable for the remainder of the
25h recording period. Following their return to pre-injection
baseline levels, the evoked potentials were no longer
different from controls (PS: F (1,18)¼0.347, NS; fEPSP: F
(1,18)¼0.025, NS). Thus, systemic injection of the higher
dose of rolipram (1.2mgkg
–1) induces a transient chemical
potentiation of synaptic strength.
Systemically administered rolipram facilitates STP into
LTP, if wHFS is applied after synaptic transmission
returns to basal levels. In this experiment (Figure 4), we
waited for more than 1h after the systemic application of the
higher dose of rolipram (1.2mgkg
–1) before tetanic
stimulation was applied. In this way, we wanted to make
sure that basal synaptic transmission was comparable
between controls and treated animals, when wHFS was
applied. The last time-point before wHFS did not differ
between controls (n¼8) and rolipram-treated animals
(n¼8) (PS: F (1,14)¼1.042, NS; Figure 4a; fEPSP: F
Figure 2 PDE4 inhibition rescues impaired LTP in MK801-treated animals in vivo.( a) Systemic (i.p.) vehicle injection does not alter the proﬁle of LTP. Control LTP, which
lasts for at least 24h is induced by HFS. No differences in PS occur between control LTP (white squares) and LTP elicited 1 week after a systemic vehicle treatment (black
squares).Linebreaksonthex-axisindicatechangeintime-scale.(b)OneweekafterasingleMK801injection(i.p.),LTPofPS(blacksquares)issigniﬁcantlyimpairedcompared
with controlLTP(white squares).Line breakson thex-axisindicate changeintime-scale. (c) Oneweek after MK801 treatment,i.c.v. applicationof thePDE4inhibitor,rolipram,
30min before HFS, fully rescues LTP (black squares). No difference in LTP proﬁle is evident compared with control LTP (white squares). Line breaks on the x-axis indicate
change in time-scale. (d) Original analog traces show ﬁeld potentials evoked from the dentate gyrus during (i) control LTP and (ii) LTP elicited 1 week after a systemic vehicle
treatment, (iii) control LTP and (iv) LTP induced one week after a systemic MK801 treatment, (v) control LTP and (v) LTP elicited 1 week after a systemic MK801 treatment in
combinationwithrolipram.Analogswereobtainedatsimilartimepoints(10minpre-HFS,10minand4hpost-HFS).Verticalscale-barcorrespondsto5mV,horizontalscale-bar
to 10ms. HFS, high-frequency stimulation; i.p., intraperitoneal; LTP, long-term potentiation; PDE4, phosphodiesterase type 4; PS, population spike.
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Translational Psychiatry(1,14)¼0.080, NS, not shown). In this case, wHFS in the
presence of rolipram still resulted in a signiﬁcantly facilitated
STP as compared with controls (PS: F (1,352)¼6.449,
Po0.05, Figure 4a; fEPSP: F (1,352)¼6.145, Po0.05; not
shown). Thus, systemic application of rolipram facilitates
STP into LTP independent of changes in basal synaptic
transmission.
PDE4 inhibition rescues object recognition memory
1 week after MK801 treatment. There were no signiﬁcant
differences in absolute exploration levels between the
different groups during T1 (F (3,36)¼0.209, NS;
Figure 5b), nor during T2 (F (3,36)¼1.364, NS; Figure 5c).
One week after i.p. treatment with MK801 (n¼10), object
recognition memory performance was signiﬁcantly impaired,
asnodifferencebetweentimespentexploringthefamiliar and
the novel objects could be observed (F (1,18)¼0.213, NS;
Figure 5e). In contrast, the control group (n¼10), treated with
saline 1 week before behavioral testing, clearly distinguished
between the familiar and the novel objects 4h after T1 (F
(1,18)¼13.813, Po0.01; Figure 5d).
If rolipram was injected s.c.24h before T2,vehicle- (n¼10)
and MK801-treated animals (n¼8), both signiﬁcantly remem-
bered the familiar object after 4h (F (1,18)¼60.691,
Po0.0001 and F (1,14)¼8.078, Po0.01, respectively;
Figures 5f and g, respectively). Thus, treatment with rolipram
prevented MK801-induced deﬁcits in object recognition
memory.
Figure 4 LTP enhancement by a subcutaneous injection of rolipram, still occurs
if tetanisation is applied after the transient rolipram-mediated increase in baseline
subsides. (a) To exclude that the transient increase in PS contributes to LTP-
facilitation by rolipram, we examined effects on LTP after the PS enhancement had
subsided. PS enhancement disappeared ca. 60min after s.c. injection of rolipram.
Tenminutes later wHFS wasapplied. Here, STPwasfacilitated into LTPby rolipram
(1.2mgkg
–1, s.c., black squares) compared with vehicle-injected controls (white
squares, the same control group as shown in Figure 3a). Line breaks on the x-axis
indicatechangeintime-scale.(b)Originalanalogtracesshowﬁeldpotentialsevoked
from the dentate gyrus during (i) wHFS with s.c. vehicle injection, (ii) wHFS with s.c.
injection of rolipram (1.2mgkg
–1). Analogs were obtained at similar time points
(10min pre-wHFS, 10min and 4h post-wHFS). Vertical scale-bar corresponds to
5mV,horizontalscale-barto10ms.HFS,high-frequencystimulation;LTP,long-term
potentiation; s.c., subcutaneously; PS, population spike.
Figure 3 Systemic application of the PDE4 inhibitor rolipram enhances
synaptic plasticity in vivo and transiently affects basal synaptic transmission. (a)
Weak HFS (wHFS) results in STP in animals treated with vehicle s.c. (white
squares). STP lasts for approximately 2h. s.c. treatment with the PDE4 inhibitor
rolipram (0.6mgkg
–1 s.c., grey squares), 30min before wHFS results in LTP, which
lasts for 4h. LTP lasts for at least 24h, if the higher dose (1.2mgkg
–1, s.c., black
squares) is applied. Line breaks on the x-axis indicate change in time-scale. (b) s.c.
treatment with the higher dose of rolipram (1.2mgkg
–1, s.c., black squares) has a
transient enhancing effect on the PS amplitude, which lasts for approximately 1h
after injection, compared with control baseline (white squares). Line breaks on the
x-axis indicate change in time-scale. (c) Original analog traces show ﬁeld potentials
evoked from the dentate gyrus during (i) wHFS with s.c. vehicle injection, (ii) wHFS
withs.c.injectionof thelow doseofrolipram,(iii) wHFSwiths.c. injectionof thehigh
dose of rolipram, (iv) test-pulse stimulation with s.c. injection of vehicle and (v) test-
pulse stimulation with s.c. injection of the high dose of rolipram. Analogs were
obtained at similar time points (10min pre-wHFS, 10min and 4h post-wHFS).
Vertical scale-bar corresponds to 5mV, horizontal scale-bar to 10ms. HFS, high-
frequency stimulation; LTP, long-term potentiation; PDE4, phosphodiesterase type
4; s.c., subcutaneously; STP, short-term potentiation.
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The present study demonstrates that PDE4 inhibition facil-
itates hippocampal LTP in freely behaving healthy animals
after intracerebroventricular (i.c.v.) as well as after systemic
(s.c.) administration, and that it rescues long-term impair-
ments in LTP and in object recognition memory that occur in
an animal model of psychosis.
Phosphodiesterases (PDEs) are enzymes that break down
cyclic nucleotides, and have an important role in intracellular
signaling. Hence, PDE inhibitors elevate concentrations of
second messengers, such as cAMPs and cyclic guanosine
monophosphates (cGMPs), thereby affecting major intracel-
lular cascades involved in synaptic plasticity.
43 The activity of
PKA is determined by cAMP, and PKA mediates factors such
as CREB
4 that triggers gene transcription, which is in turn
essential for long-lasting LTP and memory.
5,37 Rolipram is
known to selectively inhibit cAMP-speciﬁc PDE4 and to
increase cAMP levels by preventing its hydrolysis.
2,3,38,39
Our results support that this is also the case when rolipram is
injected in vivo: i.c.v. injection of rolipram increases the
hippocampal cAMP concentration. Rolipram activates the
Figure 5 PDE4 inhibition rescues impaired object recognition memory in MK801-treated animals. (a) Timeline and experimental design of the ORT study. During the T1
the animal is allowed to explore two identical objects. 4h later in the T2, the animal is exposed to a familiar and a novel object. Subcutaneous (s.c.) rolipram injection was
applied 24h before T2. i.p. treatment with MK801 or vehicle occurred 1 week before T1. (b) During T1 absolute exploration time was comparable between all groups. Values
representmeans ±s.e.m. (c) DuringT2 absoluteexploration levelsdid notdiffersigniﬁcantly betweenthe fourgroups. Values representmeans±s.e.m. *Po0.05. (d)In the
controlgroup, 1 weekafter i.p. treatmentwith vehicle,the animalsstillremember theold object after4h, as shownby a signiﬁcantlylonger explorationtimeof thenovel object
duringT2. Valuesrepresentmeans±s.e.m.;*Po0.05.(e)Animalstreatedwith MK8011weekbefore theORTdo notremember thefamiliarobject after4h, as indicatedby
equalexplorationtimesofbothobjects.(f)Controlanimals,whichweretreatedwithvehicle1weekbeforetheORT,showasigniﬁcantmemoryperformance,followingrolipram
injection 24h before T2. (g) MK801-induced memory impairment is prevented if animals are given rolipram 24h before T2. i.p., intraperitoneal; ORT, object recognition task;
PDE4, phosphodiesterase type 4; s.c., subcutaneously; T1, ﬁrst trial; T2, second trial.
PDE4 regulates LTP and memory
V Wiescholleck and D Manahan-Vaughan
8
Translational Psychiatrymitogen-activated protein kinase (MAPK) pathway via Rap1
but not Ras signaling.
35 Treatment with rolipram also
increases hippocampal expression and phosphorylation of
CREB.
40,41 Therefore, the cAMP/PKA/MAPK/CREB pathway
appears to be speciﬁcally involved in the rolipram-mediated
effects on synaptic plasticity and memory.
Behavioral studies have demonstrated an improving effect
of rolipram in memory-related tasks.
42,43 Rolipram also
enhances synaptic plasticity in the hippocampal slice pre-
paration.
2,6,35Ourstudyistheﬁrstonetocompletethispicture
of evidence, in vivo, by demonstrating that PDE4 inhibition
also facilitates hippocampal LTP in the intact brains of freely
behaving rats.
Although primarily known from the neuroenhancement
research area
44 and from aborted clinical trials as an
antidepressant,
45,46 recent behavioral studies indicate a
possible therapeutic role of PDE4 inhibition in psychosis-
related diseases.
21,29 On the molecular level, common
antipsychotics primarily block the dopamine D2-receptors
and thereby cause an increase in cAMP,
21,47 implying a
possible therapeutic potential for cAMP-concentration-elevat-
ing PDE inhibitors in schizophrenia spectrum disorders. Of
note, no currently available antipsychotics are able to
treat schizophrenia-related cognitive dysfunctions.
48 In this
respect, PDE4 might be a more promising target.
Inthisstudy,wedemonstratedthatPDE4inhibitionprevents
MK801-induced long-term deﬁcit in the ability to express LTP
in freely moving rats. Through application of rolipram 1 week
after MK801 treatment, LTP was enabled that lasted for over
24h. Speciﬁcally, the maintenance phase was fully rescued.
This is in line with the ﬁnding that cAMP has a role primarily in
the later phase of LTP,
49 as well as in long-term rather than in
short-term memory.
1 In parallel, demonstrating a functional
aspect of these electrophysiological ﬁndings, we found that a
single MK801 treatment leads to long-term impairments in
object recognition memory and that PDE4 inhibition prevents
these MK801-induced memory deﬁcits. In our behavioral
study, animals were treated with rolipram 20h before the ﬁrst
trialoftheORT.Thus,theabilityofrolipramtopreventMK801-
induced deﬁcit in object recognition memory lasted far beyond
its half-life time of 1–3h.
50 Others have already demonstrated
persistent effects of subchronic
1,40 and chronic
41,51 rolipram
treatment. Our behavioral and electrophysiological results
indicate that an acute injection with rolipram is sufﬁcient to
trigger molecular changes related to memory and synaptic
plasticity lasting for more than 20h. Presumably, this happens
via activation of CREB-dependent gene expression.
Besides suggesting a possible therapeutic target, these
ﬁndings also give us insights into potential pathophysiological
mechanisms underlying schizophreniform psychosis. Why
are plasticity and object recognition memory still impaired 1
week after an acute MK801-induced psychotic event? Which
mechanisms lead to the ability of PDE4 inhibition to restore it?
Our animal model is based on the NMDAR-hypofunction
hypothesis of schizophrenia,
52,53 which assumes that a
deﬁciency in NMDAR functioning has a major role in
schizophreniform pathology. If given systemically, MK801
increases spontaneous ﬁring rates in the medial prefrontal
cortex, speciﬁcally via a hippocampo-prefrontal pathway.
54
Thus, among these two main schizophrenia-related brain
structures, the medial prefrontal cortex and the hippocampus,
the latter seems to be activated ﬁrst by MK801. However,
presumably effects within both regions and their circuits
lead to the overall psychotomimetic proﬁle of MK801.
After a single application of MK801, a high proportion of
NMDARs are irreversibly blocked.
55 This treatment results in
a physiological long-term change, which lasts for at least 1
week, as reﬂected by the impairment of synaptic plasticity and
object recognition memory that we have observed in our
study. The mechanism underlying this effect may relate to
NMDAR hypofunction resulting from a loss of receptors but
also to a functional impairment of the receptor itself. This
possibility is supported by ﬁndings that increasing available
glycine rescues impaired LTP in the same MK801 animal
model.
17 However, our current ﬁnding that impaired LTP is
also rescued by PDE4 inhibition suggests that alterations of
the cAMP concentration in the brain might additionally have
an important rolein this phenomenon. Indeed,some evidence
exists for a possible direct link between NMDARs and cAMP
levels. For instance, Skeberdis et al.
56 have shown that PKA
regulates Ca
2þ-inﬂux through NMDARs in vitro. Speciﬁcally,
this study demonstrated that the Ca
2þ permeability of
neuronal NMDARs is controlled by the cAMP-PKA signaling
cascade.PKAinhibitionledtoadecreasedNMDAR-mediated
Ca
2þ-rise in activated dendritic spines, indicating that PKA
might also have a role in the regulation of both the induction
and maintenance of LTP.
Another interesting link in this respect is provided by the
fact that the NR1 subunit of the NMDAR is phosphorylated
by PKA at the S897 site and that mice deﬁcient for this
phosphorylation display a schizophrenia-relevant behavioral
proﬁle.
57 Additionally, the phosphorylation at this site has
been shown to be reduced in schizophrenic patients.
58
Zhang et al.,
28,59 have shown that inhibition of PDE4
reversesmemorydeﬁcitsassociatedspeciﬁcallywithNMDAR
antagonism. Moreover, PDE4 inhibitor rolipram has been
demonstrated to enhance the ability of NMDA to increase
cAMP in neurons. This effect could be antagonized by
application of MK801.
60 Finally, it has been recently reported
that cAMP production is modulated by PDE4 in response to
NMDAR stimulation via a pharmacological NMDAR agonist in
mouse cortical neurons, thereby providing another link
between NMDAR-functioning and PDE4 (source: schizophre-
nia research forum website).
61
Despite these ﬁrst pieces of evidence, it remains spec-
ulative as to whether cAMP levels depend on the NMDAR,
if they change as a consequence of NMDAR hypofunction,
or if cAMP itself has a causative role in this respect by
inﬂuencing NMDARcurrents. ItisfurthermoreunclearifPDE4
inhibition rescues MK801-induced deﬁcits by ‘kicking-in’ at a
more downstream level of NMDAR-dependent signaling
cascades, leaving the dysfunctional upstream part unaf-
fected, or if elevated cAMP levels directly interact with
NMDARs, thereby restoring relevant cascades at an early
phase of the process. The latter point is supported by in vitro
datathatsuggestthatPDE4andDISC1associatewithNR1,a
mandatory NMDAR-subunit (source: schizophrenia research
forum website.)
61
In order to further study the therapeutic potential of PDE4
inhibition, it isimportant tosee if rolipram woulddisplay similar
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application.Weshowherethatasystemicinjectionofrolipram
has similar beneﬁcial effects as an application directly into the
brain.Behavioralstudieshavealreadyindicatedthatsystemic
application of rolipram leads to an enhanced effect on
cognitive performance,
1,2,41 and our study suggests a
possiblemechanismunderlyingthiseffect:namely,facilitation
ofhippocampalsynapticplasticity.Ourdata supportthat,after
peripheral administration in vivo, rolipram reaches the
hippocampus, the brain structure that is most prominently
involved in learning and memory processes, and facilitates its
ability to express LTP on the cellular level. Interestingly, a
high-dose subcutaneous injection induced a transient poten-
tiation of PS, suggesting that a brief increase in somatic
excitability occurred. This ﬁnding is interesting in its own right
as it suggests that rolipram is able to enhance cellular
excitability in the absence of external electrical stimulation.
Higher doses of rolipram could be expected to prolong the
duration of this chemical potentiation, and this may also have
interesting therapeutic implications.
Nonetheless, although PDE4 inhibition displays an inter-
esting new target with neuroenhancing and therapeutic
potential and although rolipram provides a valuable tool in
order to study this mechanism of action, this particular
substance has to be ﬁrst pharmacologically tuned in order to
make it relevant for clinical consideration. A known side-effect
of rolipram is nausea.
46 And indeed, we also observed
transient dizziness in our rats right after a systemic injection
of the higher dose of rolipram. This emetic effect makes it
rather difﬁcult to test rolipram in human trials. Additionally, as
molecular evidence has shown speciﬁcally PDE4B to be a
genetic susceptibility factor for schizophrenia,
23 more sub-
type-selective PDE4 inhibitors would be interesting to study in
future.
In conclusion, our results support that treatment with a
PDE4 inhibitor facilitates synaptic plasticity in the intact brains
of healthy animals and restores impaired LTP and object
recognition memory in an animal model of psychosis. These
data provide further insight into possible mechanisms under-
lying psychosis pathology. We suggest that the antipsychotic-
like proﬁle of PDE4 inhibition is mediated, in part, by a rescue
of impaired LTP that enables improved hippocampus-depen-
dent cognition.
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